Shots:
- BI & Cue Biopharma have entered into a multi-year strategic research & license agreement to develop & commercialize CUE-501 for autoimmune diseases, with the potential to expand into other B cell-targeting bispecifics using Cue’s Immuno-STAT platform
- As per the deal, Cue Biopharma will receive a $12M upfront & ~$345M in research, development, & commercial milestones, starting with 2 preclinical milestones, plus research support payments & net sales-based royalties
- CUE-501 is a preclinical candidate that targets a B cell-specific membrane protein while engaging virus-specific memory T cells, allowing selective B cell depletion to reduce autoimmune & inflammatory responses
Ref: Globenewswire | Image: Cue Biopharma & Boehringer Ingelheim
Related News:- Boehringer Ingelheim Introduces Vaxxitek HVT+IBD+H5 Vaccine Against Marek’s Disease, Infectious Bursal Disease and H5 Avian Influenza
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
